Mitapivat · Pyrukynd
Small molecule
Also known as AG-348
Evidence outlook
Approved: Pyruvate Kinase Deficiency
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Latest reported trial: NCT03548220 · Phase 3 · met primary endpoint · grade pending
Also in development:Sickle Cell Disease · Phase 3 · investigational in the US · under FDA reviewTransfusion-Dependent Beta Thalassemia · Phase 3 · investigational in the USapproved in the US as Aqvesme (same FDA application)
Also approved (5)
- Adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia (release dated 2026-05-22)
- Treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (holder Agios Netherlands B.V.)
- Adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (Agios release dated 2026-03-02)
- Adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (Agios release dated 2025-08-04)
- Treatment of PK deficiency in adult patients (Great Britain, via EC Decision Reliance Procedure)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03548220 NCT03548220 · Pyruvate Kinase Deficiency ACTIVATE was a randomized, double-blind, placebo-controlled Phase 3 trial in 80 adults with pyruvate kinase deficiency who were not regularly transfused. The single primary endpoint was hemoglobin response, a sustained rise of at least 1.5 g/dL during the fixed-dose period. Of the 40 patients on mitapivat, 16 (40%) responded against none of the 40 on placebo (p<0.0001), so the primary endpoint was met. Sources: the FDA label (PYRUKYND) and the CT.gov posted results. Registry: NCT03548220 | 3 | Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR) (Baseline, Weeks 16, 20, 24) 2020-10-09 | Hemoglobin response (an increase of at least 1.5 g/dL from baseline sustained at 2 or more of Weeks 16, 20 and 24, without transfusion): 16 of 40 (40%) with mitapivat vs 0 of 40 with placebo; difference 39 percentage points (95% CI 24 to 55), p<0.0001 (PYRUKYND label Table 6; CT.gov posted results). | not yet graded | link ↗ |
View 1 more trial
NCT03559699 NCT03559699 · Pyruvate Kinase Deficiency Registry: NCT03559699 | 3 | Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2 (From Part 2, Day 1 to Part 2 Week 24) 2020-11-12 | Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2 (From Part 2, Day 1 to Part 2 Week 24): AG-348 37 percentage of participants (95% CI 19.4 to 57.6) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Pyruvate kinase drugs
Mitapivat (Aqvesme), Etavopivat. Compare all 3 Pyruvate kinase drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Sickle Cell Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mitapivat (Pyrukynd): this drug | Phase 3 | Small molecule | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Crizanlizumab-Tmca (Adakveo) | Approved | Monoclonal antibody | P-selectin | Partial signal | Featured results are non-efficacy only in this race | |
| Exagamglogene Autotemcel (Casgevy) | Approved | Gene therapy / editing | BCL11A erythroid enhancer (gene editing) | Weak signal | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Droxia) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Siklos) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Xromi) | Approved | Small molecule | Ribonucleotide reductase | Weak signal | No reviewed efficacy summary in this indication | |
| L-Glutamine (Endari) | Approved | Small molecule | Amino Acid | Reliable signal | NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15) | |
| Lovotibeglogene Autotemcel (Lyfgenia) | Approved | Gene therapy / editing | Beta-globin gene addition (betaA-T87Q) | not yet graded | No reviewed efficacy summary in this indication | |
| Etavopivat | Phase 3 | — | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Decitabine / Tetrahydrouridine (NDec) | Phase 2 | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | not yet graded | No reviewed efficacy summary in this indication | |
| ITU512 | Phase 1/2 | Small molecule | WIZ transcription factor | not yet graded | No reviewed efficacy summary in this indication | |
| Nula-Cel | Phase 1/2 | Gene or cell therapy (subtype unspecified) | HBB gene (sickle mutation correction) | not yet graded | No reviewed efficacy summary in this indication | |
| Ristoglogene Autogetemcel | Phase 1/2 | Gene therapy / editing | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| DISC-3405 | Phase 1 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication | |
| SCD-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| VAS-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Renizgamglogene Autogedtemcel | Discontinued | Gene or cell therapy (subtype unspecified) | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | Reliable signal | NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92 |
Compare side by side
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Pyrukynd (Mitapivat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
February 2028 (1)
What to watch
September 2028 (1)
What to watch
2029 (5)
March 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (2)
October 2029 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent